Topical and transdermal delivery with diseased human skin: passive and iontophoretic delivery of hydrocortisone into psoriatic and eczematous skin

Bozorg, Behnam Dasht; Bhattaccharjee, Sonalika Arup; Somayaji, Mahadevabharath R.; Banga, Ajay K.

doi:10.1007/s13346-021-00897-7

Cited by 14 publications

(7 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are currently no controlled clinical studies with human patients that assessed the suitability of this method for atopic dermatitis drugs. In vitro data using human skin preparations revealed transdermal delivery of hydrocortisone, albeit similar efficacy was obtained by passive diffusion when healthy skin was tested [57]. However, iontophoresis resulted in significantly higher absorbance of hydrocortisone than passive diffusion when eczematous skin and psoriatic skin were tested [58].…”

Section: Iontophoresismentioning

confidence: 80%

Novel Vehicles For Drug Delivery In Atopic Dermatitis: A Narrative Review

Farkouh,

Anthony,

Abdi

et al. 2023

Dermatol Pract Concept

View full text Add to dashboard Cite

Introduction: Atopic dermatitis (AD) causes dry and itchy skin and inflammation that severely impairs the quality of life of affected children and adults. While topical glucocorticosteroid application is typically the first-line treatment of choice, steroid treatment is associated with side effects and, increasingly, patient concerns about prolonged use. Novel drugs and drug delivery vehicles are required for patients with AD. Objective: To summarize the current literature on novel topical agents for atopic dermatitis and novel delivery vehicles. Methods: A literature search was conducted, and a narrative review was compiled to summarize recent evidence. Results: Novel topical drugs approved or in late-phase clinical trials for the treatment of AD include the Janus kinase inhibitor ruxolitinib, the phosphodiesterase-4 inhibitors crisaborole, and roflumilast, and the aryl hydrocarbon receptor activator tapinarof. While current topical drugs for AD are delivered via creams, ointments, gels, and related vehicles, novel delivery approaches such as electrospun patches, sprays, liposomes, nanoparticles, and lasers are being developed to enhance transdermal delivery, reduce side effects, and increase treatment adherence. Conclusion: Topical application of creams or ointments is currently the predominant vehicle for the delivery of atopic dermatitis drugs. In vitro studies on novel vehicles show promising results to overcome the issues associated with topical delivery. Still, these findings have to be corroborated by controlled studies with human patients in the future.

show abstract

Section: Iontophoresismentioning

confidence: 80%

Novel Vehicles For Drug Delivery In Atopic Dermatitis: A Narrative Review

Farkouh,

Anthony,

Abdi

et al. 2023

Dermatol Pract Concept

View full text Add to dashboard Cite

show abstract

“…Thirdly, the manufacturing methods of transdermal drug delivery systems are relatively mature. Fourthly, the drug delivery sites are flexible and can be adjusted on demand [ 9 ]. Due to these advantages, transdermal drug delivery systems have gained significant interest in the pharmaceutics arena and related fields.…”

Section: Transdermal Drug Delivery System: a Rising Starmentioning

confidence: 99%

The Necessity to Investigate In Vivo Fate of Nanoparticle-Loaded Dissolving Microneedles

Chang,

Wu,

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Transdermal drug delivery systems are rapidly gaining prominence and have found widespread application in the treatment of numerous diseases. However, they encounter the challenge of a low transdermal absorption rate. Microneedles can overcome the stratum corneum barrier to enhance the transdermal absorption rate. Among various types of microneedles, nanoparticle-loaded dissolving microneedles (DMNs) present a unique combination of advantages, leveraging the strengths of DMNs (high payload, good mechanical properties, and easy fabrication) and nanocarriers (satisfactory solubilization capacity and a controlled release profile). Consequently, they hold considerable clinical application potential in the precision medicine era. Despite this promise, no nanoparticle-loaded DMN products have been approved thus far. The lack of understanding regarding their in vivo fate represents a critical bottleneck impeding the clinical translation of relevant products. This review aims to elucidate the current research status of the in vivo fate of nanoparticle-loaded DMNs and elaborate the necessity to investigate the in vivo fate of nanoparticle-loaded DMNs from diverse aspects. Furthermore, it offers insights into potential entry points for research into the in vivo fate of nanoparticle-loaded DMNs, aiming to foster further advancements in this field.

show abstract

“…The results demonstrated that enalapril iontophoresis considerably reduced the signs and symptoms of skin lesions in mice with experimental psoriasis, and this method had a therapeutic effect that was superior to that of enalapril intradermal injection. Dasht Bozorg et al investigated differences in transdermal absorption of ionized administration in healthy or injured skin when using iontophoresis hydrocortisone to treat psoriasis and eczema [ 19 ]. They also compared passive transport and iontophoresis administration for efficacy.…”

Section: Development Of the Tddsmentioning

confidence: 99%

Advance and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System

Cheng,

Tai,

Shen

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Skin diseases are among the most prevalent non-fatal conditions worldwide. The transdermal drug delivery system (TDDS) has emerged as a promising approach for treating skin diseases, owing to its numerous advantages such as high bioavailability, low systemic toxicity, and improved patient compliance. However, the effectiveness of the TDDS is hindered by several factors, including the barrier properties of the stratum corneum, the nature of the drug and carrier, and delivery conditions. In this paper, we provide an overview of the development of the TDDS from first-generation to fourth-generation systems, highlighting the characteristics of each carrier in terms of mechanism composition, penetration method, mechanism of action, and recent preclinical studies. We further investigated the significant challenges encountered in the development of the TDDS and the crucial significance of clinical trials.

show abstract

Topical and transdermal delivery with diseased human skin: passive and iontophoretic delivery of hydrocortisone into psoriatic and eczematous skin

Cited by 14 publications

References 75 publications

Novel Vehicles For Drug Delivery In Atopic Dermatitis: A Narrative Review

Novel Vehicles For Drug Delivery In Atopic Dermatitis: A Narrative Review

The Necessity to Investigate In Vivo Fate of Nanoparticle-Loaded Dissolving Microneedles

Advance and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System

Contact Info

Product

Resources

About